中低收入国家公平准入的新模式_The new model for equitable access in LMICs_Aug 2025.docxVIP

Thenewmodelfor

equitableaccessinLMICs-Frominitiativeto

integratedecosystems

Howpharmaceuticalleadersare

successfullyembeddingequitableaccessintostrategy,structure,

andscaleacrossLMICs

Contents

Executivesummary3

Chapteroverview4

1.Rethinking“emergingmarkets”andthenewmandate

forequitableaccess6

2.Theexecutiongap14

3.Navigatingcomplexitiesandexploringblueprintsforsuccess23

Outlook:Buildingfuture-readyequitableaccessplatforms36

Authors40

3

Executivesummary

Foryears,accesseffortsinlow-andmiddle-incomecountries(LMICs)focusedlargelyoninfectiousdiseaseslikeHIV,tuberculosis,andmalaria,supportedbydonorfunding,one-offprograms,orfragmentedpublic-privatepartnerships.Thesemodelsbroughtprogress,buttheywerenotbuiltforsustainabilitynorscale.Asnon-communicable

diseases(NCDs)havebecomemoreprevalent,thishaspromptedashifttowardmoreintegrated,long-termaccessmodels.

Withover80%oftheworld’spopulationresidinginLMICs,itisnolongersurprisingthatthesegeographiesarerisingtothetopofcorporateagendas.Theirscalealonemakes

themcentraltothefutureofglobalhealthcareaccessandinnovation.

LMICsarebeginningtooccupyamorecentralplaceinpharma

executives’discussions,notjustasgrowthmarkets,butas

strategicpriorities.Ashealthcaresystemsintheseregions

evolve,pharmaandbiotechcompaniescompaniesarerethinkinghowtheydefinerelevance,access,andlong-termimpact.

Withrisingpopulations,increasedlifeex